HSD17B13 - Potential target for NAFLD research

HSD17B13 (17-β-hydroxysteroid dehydrogenase type 13) is a member of the HSD17Bs superfamily and has a known biological function in hepatic lipid metabolism. It has been identified as a new liver-specific lipid droplet-associated protein involved in developing non-alcoholic fatty liver disease (NAFLD). Various treatments and drug development studies targeting different splicing variants of HSD17B13 have shown promising results, indicating HSD17B13 as a potentially therapeutic target.

OriGene offers a range of tools for analyzing HSD17B13

Featured Products:

Human Recombinant Protein

Rabbit Monoclonal Antibody

ELISA Kit

TP313132

TA592047

EA200008

Bioactive human HSD17B13 recombinant protein with high specific activity Rabbit monoclonal HSD17B13 Antibody, Clone OTIR5C10 for WB, IHC applications Quantitative detection of human HSD17B13 in serum, plasma, and cell lysates
Human Recombinant Protein
HSD17B13 enzymatic activity with 75μM β-estradiol as a substrate, measured by NADH production (indicated by luminescence).
Rabbit Monoclonal Antibody
Carcinoma of Human liver tissue stained using anti-HSD17B13 rabbit monoclonal antibody.
ELISA Kit
Human HSD17B13 ELISA kit provides sensitivity as low as 100 pg/mL

Application in Research:

OriGene's products play a crucial role in HSD17B13-related research, as demonstrated by frequently cited in well-reputed journals. Sven T. et al. used recombinant human HSD17B13 (OriGene: TP313132) to discover a novel HSD17B13 inhibitor using a high-throughput screening method (Figure 1)1. Quentin A. et al. used recombinant human HSD17B13 (OriGene: TP313132) to develop a bioluminescent retinol dehydrogenase assay for HSD17B13.2

Evaulation of the risk for substrate-biased hits.
Figure 1. Evaluation of the risk for substrate-biased hits.

Interested in other HSD17B products? Click Here

References

  1. Sven et al. 2023 Feb. doi: 10.1016/j.jhep.2020.04.003
  2. Quentin et al. 2021 Nov. doi: 10.1021/acs.jmedchem.2c01884